Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary03/13/2018
PHILADELPHIA , March 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the three and twelve months ended December 31, 2017 . Fourth Quarter and Year-End Corporate Highlights Continued advancing and strengthening
Toggle Summary03/07/2018
-Early stage program in an ultra-orphan pediatric indication with potential to expand to additional indications post proof of concept. PHILADELPHIA , March 7, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ MKT: GNMX) today announced that it has expanded its collaboration with Kyowa Hakko
Toggle Summary03/06/2018
PHILADELPHIA , March 6, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Tuesday, March 13, 2018 at 8:30 a.m. EDT  to report financial results for the fourth quarter and year ended December 31,
Toggle Summary12/04/2017
PHILADELPHIA , Dec. 4, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today the appointment of Matthew D. Bayley , MD, MBA to its Board of Directors. "We are excited to welcome Matt to our Board of Directors during this important time for the Company," said
Toggle Summary11/02/2017
PHILADELPHIA , Nov. 2, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended September 30, 2017 and provided a corporate update. Third Quarter and Recent Corporate Highlights Initiated screening and
Toggle Summary10/17/2017
PHILADELPHIA , Oct. 17, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)(the " Company ") today announced the completion of a previously announced private placement of 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares of
Toggle Summary09/05/2017
PHILADELPHIA , Sept. 5, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 19th Annual Global Investment at 2:35 PM EDT in New York, NY on Monday,
Toggle Summary08/10/2017
PHILADELPHIA , Aug. 10, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") today announced the execution of a definitive agreement to sell shares of common stock and warrants to purchase common stock in a private placement, or PIPE, to certain accredited investors, led
Toggle Summary08/09/2017
PHILADELPHIA , Aug. 9, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided a corporate update. Second Quarter Corporate Highlights Initiating Phase 2 clinical trial in
Toggle Summary06/13/2017
PHILADELPHIA , June 13, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will be a participant on the Emerging Landscape of Orphan / CNS Disorders Panel at the JMP Securities Life Sciences